HCP
ANIK icon

Hexagon Capital Partners’s Anika Therapeutics ANIK Stock Holding History

Hexagon Capital Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8
Closed -$132 – 1837
2024
Q4 		$132 Buy
+8
New +$158 ﹤0.01% 1802

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Hexagon Capital Partners's ANIK Position: Q1 2025 in Review

Hexagon Capital Partners sold out of Anika Therapeutics (ANIK) in Q1 2025, closing a stake of 8 shares — an estimated $132 sold.

Hexagon Capital Partners first reported a position in ANIK in Q4 2024 and held it in 1 quarter. The position peaked at $132 in Q4 2024. 108 funds tracked by Wall St. Rank hold ANIK as of Q1 2025.

  • Hexagon Capital Partners reported no remaining Anika Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 8 Anika Therapeutics shares in Q1 2025, an estimated $132.
  • Hexagon Capital Partners first reported a position in Anika Therapeutics in Q4 2024 and held it in 1 quarter.
  • Hexagon Capital Partners's Anika Therapeutics position peaked at $132 in Q4 2024.
  • 108 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2025.

Based on Hexagon Capital Partners's 13F filing for Q1 2025, filed 29 Apr 2025.